California State Teachers Retirement System lifted its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 65.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,390 shares of the company’s stock after purchasing an additional 25,900 shares during the quarter. California State Teachers Retirement System owned about 0.15% of Global Blood Therapeutics worth $1,788,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of GBT. UBS Asset Management Americas Inc. purchased a new position in Global Blood Therapeutics in the first quarter worth about $597,000. Parametric Portfolio Associates LLC purchased a new position in Global Blood Therapeutics in the first quarter worth about $1,130,000. American International Group Inc. grew its position in Global Blood Therapeutics by 24.1% in the first quarter. American International Group Inc. now owns 10,031 shares of the company’s stock worth $370,000 after acquiring an additional 1,945 shares in the last quarter. Teachers Advisors LLC grew its position in Global Blood Therapeutics by 426.2% in the first quarter. Teachers Advisors LLC now owns 156,195 shares of the company’s stock worth $5,756,000 after acquiring an additional 126,513 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in Global Blood Therapeutics by 40.5% in the first quarter. TIAA CREF Investment Management LLC now owns 130,606 shares of the company’s stock worth $4,813,000 after acquiring an additional 37,672 shares in the last quarter. 86.76% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now owns 140,055 shares in the company, valued at $4,201,650. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles J. Homcy sold 70,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold 91,500 shares of company stock valued at $3,093,350 in the last 90 days. Company insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/california-state-teachers-retirement-system-raises-stake-in-global-blood-therapeutics-inc-gbt/1708926.html.

Global Blood Therapeutics, Inc. (GBT) opened at $40.05 on Friday. Global Blood Therapeutics, Inc. has a 12-month low of $13.35 and a 12-month high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last announced its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter last year, the firm posted ($0.58) earnings per share. sell-side analysts expect that Global Blood Therapeutics, Inc. will post -2.53 EPS for the current year.

Several research analysts recently commented on the company. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company reiterated an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. set a $53.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. Finally, Zacks Investment Research lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $55.00.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.